Japan: medical and donor requirements for surrogacy
Short answer
Japan's medical and donor rules for surrogacy cannot be reduced to one statutory eligibility checklist. As of this guide, dated 24 October 2026, the sources show a law setting general principles for assisted reproductive technology (ART) and limited parentage rules, a longstanding professional position against surrogacy, and clinic-specific acceptance criteria. They do not establish a national route under which a person qualifies merely by passing medical tests. Two decisions must be separated: whether a Japanese provider will offer the exact procedure under its professional standards, and what legal consequences follow if pregnancy and birth occur. Neither a clinic's willingness nor a donor's medical clearance resolves the other question.
Separate law, professional rules and clinic policy
Keep three levels separate. First, Act No. 76 of 2020 on assisted reproductive technology sets general principles and special parentage rules. Second, views of the Japan Society of Obstetrics and Gynecology (JSOG) guide participating clinicians; they are not an Act of the Diet and do not automatically bind every provider. Third, a clinic may add its own eligibility, testing, counselling, documentation and embryo-transfer criteria. Clinic policy may be stricter than a statute or determine what is offered where legislation is silent, but it cannot create nationwide law or guarantee that a surrogacy agreement is enforceable. The official bill-history entry records referral of the 2025 specified-ART bill to the House of Councillors Cabinet Committee on 30 May 2025, an unresolved examination status, and no promulgation date. That entry concerns only that bill and session; it does not establish that no later proposal exists.
What the 2020 Act does—and does not—say
Act No. 76 includes artificial insemination, in-vitro fertilisation (IVF), and IVF embryo transfer within ART. Article 3 requires appropriate treatment in light of recipients' physical and mental condition, protection of the health of the woman who becomes pregnant and gives birth, necessary and appropriate explanations, and treatment based on participants' sufficiently informed wishes. Article 5 calls on medical personnel to endeavour to provide appropriate, good-quality treatment. These are statutory principles, not a detailed surrogate-or-donor checklist: the Act does not prescribe one nationwide set of age, body-mass-index, obstetric-history, ovarian-reserve or infection-test thresholds for every case. Article 9 says that when a woman gives birth through ART using another woman's egg, the woman who gives birth is the mother. Article 10 addresses a wife's pregnancy through ART using another man's sperm with her husband's consent. Article 3 also addresses safety in collecting and managing sperm and ova and due consideration for the child's healthy birth and development. The special parentage provisions in Chapter III took effect on 11 December 2021 and apply to children born on or after that date. Where the statutory conditions are met, Article 10 prevents a consenting husband from denying the child's legitimacy under Civil Code Article 774. These provisions do not create a comprehensive surrogacy-approval procedure or a uniform donor-eligibility checklist; Japanese counsel should apply the exact statutory wording to the procedure and facts.
The professional position on surrogacy
JSOG's 2003 view states that it does not accept surrogacy, and later Society materials continue to describe that position. This is highly relevant when assessing a Japanese fertility clinic connected with JSOG. The MHLW report describes the earlier Japanese framework as professional self-regulation centred on JSOG, not a statute that itself binds every provider. 'Not a statutory ban' does not mean that a clinic will provide the treatment, that a member can disregard professional rules without consequences, or that the arrangement is legally safe. An MHLW expert report from 2003 also recommended that surrogacy be prohibited, but an expert recommendation is not itself an enacted prohibition.
Donor sperm and donor eggs
Donor sperm and donor eggs are governed by different practical frameworks. AID (artificial insemination with donor semen) has long been addressed by JSOG professional views. A Japan Association of Obstetricians and Gynecologists overview describing the position as of April 2025 says AID is restricted in practice under JSOG rules to legally married couples and anonymous donors. Treat this as a professional standard for participating practice, not a universal statute for every use of donor sperm. For donor eggs, the professional overview reports no specific statutory treatment regulation and says clinical use in Japan is limited to a small number of facilities; a JAOG page reports use with JISART ethics-committee approval. These are descriptions of practice, not a nationwide licence or a guarantee that a clinic accepts the proposed procedure. Donor-sperm AID, IVF using donor gametes, embryo donation, and transfer to a gestational carrier are distinct scenarios. The draft retains the legal-marriage criterion for recipients and proposes donor health, infection, hereditary-disease and semen-quality checks, use of cryopreserved sperm, and a limit of 10 children or 5 families per donor. It also contemplates a transition in which anonymous and non-anonymous donor arrangements coexist, with different recordkeeping purposes. The explanatory text says that retaining records for 100 years is desirable where a child is born and calls for efforts to respect an adult child’s opportunity to meet the donor. As of 24 October 2026, JSOG had not published a formal adoption of the draft.
Medical eligibility and screening
The reviewed Act does not set one national medical-eligibility schedule for surrogates or gamete donors. The sources did not establish a universal statutory age limit, body-mass-index range, required number of previous births, ovarian-reserve threshold or exhaustive list of disqualifying diagnoses. That does not prove that no other general medical, professional or clinic rules exist. A number quoted by a clinic should be identified as its protocol or a professional guideline unless the provider points to a binding legal provision. A clinic may assess the carrier's obstetric and gynaecological history, physical and mental health, pregnancy risks, informed-consent capacity and access to antenatal and delivery care. For donors, it may assess infectious-disease risk, medical and genetic history, sample quality and consent to the intended use and data retention. These are clinically relevant screening topics, not a nationwide statutory test list. The MHLW's 2003 report discussed infection precautions for donor sperm, including HIV risk, but is not a current binding national testing schedule.
Consent and records
Consent should be treated as a process, not merely a signature. Article 3 requires appropriate explanations and treatment based on participants' sufficiently informed wishes. Request separate written explanations for medical procedures and risks; use and storage of gametes or embryos; withdrawal rights and deadlines; donor anonymity or future disclosure; storage or destruction; data retention; and what happens if treatment fails or a serious complication occurs. Ask who is responsible for each record and who may access it. A consent form does not settle legal parentage or make an otherwise unenforceable contract enforceable. Each participant should have a real opportunity to ask questions and obtain independent advice before consenting.
Decision matrix
Decision matrix: what the sources actually establish. Binding law provides general health-protection, explanation and consent principles plus limited parentage rules; it is not a statutory approval route for surrogacy or a universal clinical eligibility chart. JSOG states a professional position against surrogacy, while the 2003 MHLW report recommended prohibition; neither document is itself an enacted nationwide surrogacy ban. For donor sperm/AID, professional rules are reported to limit practice to legally married couples and anonymous donors; confirm the current rule and exact technique. For donor eggs, the professional overview reports no specific statutory regime, limited use and possible ethics review. Individual clinical thresholds vary and need a written source. A February 2026 JSOG revision draft also proposes donor-sperm IVF and changes to donor-record practices, but formal adoption was not confirmed as of 24 October 2026.
| Category | Practical status |
|---|---|
| Statute | General health, explanation and consent principles plus limited parentage rules; no statutory surrogacy approval route. |
| Professional position | JSOG opposes surrogacy; the 2003 MHLW report recommended prohibition. Neither is itself a nationwide statute. |
| Donor sperm / AID | As of the April 2025 overview, practice was described as limited to legally married couples and anonymous donors. A February 2026 JSOG revision draft proposes donor-sperm IVF and changed donor-record rules; formal adoption is not known as of October 2026. |
| Donor eggs / clinic | No specific statutory regime identified; limited use and ethics review are reported. Clinic thresholds vary. |
Questions to obtain in writing
Before paying a deposit or starting medication, ask the provider to answer in writing: (1) Does it perform the exact proposed procedure in Japan, including surrogacy, or only ordinary ART? (2) Which named professional guideline does it follow, and is it a JSOG member facility? (3) Which tests and thresholds apply separately to the carrier, egg donor, sperm donor and intended parent, and what source makes each mandatory? (4) Who reviews medical suitability, and is ethics-committee approval required? (5) Is the donor known or anonymous, what identifying and non-identifying data are recorded, and for how long? (6) What consent can be withdrawn, until when, and what happens to samples or embryos? (7) What records, clinical reports and adverse-event procedures are supplied? (8) Which Japanese lawyer can explain parentage consequences independently of the clinic? The analysis may change depending on the exact technique, egg source, genetic relationship of the carrier, marital status and consent where relevant, clinic affiliation, and whether any step occurs abroad. Request current written policies and blank consent forms before committing. Separately, ask whether JSOG formally adopted the February 2026 donor-sperm revision draft and which current version and date the clinic follows.
Errors, cross-border risks and next steps
Avoid four errors: do not describe the 2003 MHLW recommendation as a criminal statute; do not describe JSOG's professional position as a nationwide Act of the Diet; do not turn clinic screening criteria into national legal rules; and do not infer parentage from genetics, treatment approval or an intended-parents' contract. If a Japanese clinic refuses treatment, treatment abroad may be considered, but it does not automatically resolve Japanese parentage, birth registration, nationality, immigration or return travel. This guide addresses medical and donor conditions only. Before relying on a foreign programme, obtain separate advice on the birth jurisdiction and each intended parent's country of nationality or residence. Have Japanese counsel check current legislation and case law, including the 2020 Act's effect for the exact egg source and person giving birth. Do not treat the absence of a national checklist as permission to proceed; confirm the clinic's acceptance and cancellation terms before making any non-refundable payment. Also verify whether JSOG has formally adopted the February 2026 donor-sperm revision draft; do not treat it as a current rule unless adoption and the applicable version are confirmed.
Legal sources and publication status
Legislative status and professional practice can change. The February 2026 JSOG donor-sperm document was accessed as a revision draft; its formal adoption is not known as of October 2026.
- [S1] e-Gov Japan — Act No. 76 of 2020 (Japanese statutory text)
- [S2] Japanese Law Translation — Act on Assisted Reproductive Technology Offering (English translation)
- [S3] MHLW — Expert working-group material on assisted reproduction and surrogacy (2003)
- [S4] JSOG — explanatory materials on surrogacy (2023 PDF)
- [S5] JAOG — overview of AID and regulation of reproductive medicine (page describes April 2025 status)
- [S6] JAOG — educational page on egg donation and JISART ethics review
- [S7] House of Representatives, Japan — official bill history for specified assisted reproductive technology
- [S8] House of Representatives, Japan — official Diet bill index (dynamic page)
- [S9] JSOG — Draft revision of guidance on donor-sperm insemination and IVF (February 2026; adoption not confirmed)
